3 research outputs found
Disturbances in myocardial diastolic and vascular function with the emphasis on type 2 diabetes : Diagnostic and therapeutic opportunities
Background and aims
Cardiovascular involvement is common in diabetes and diastolic myocardial
and endothelial dysfunction are early signs. The prognosis is serious and
tools for early detection and a search for improved management strategies
are important. This thesis explores tools for the early detection of
myocardial involvement and examines whether intensive glucose control
could improve diastolic and endothelial dysfunction in patients with type
2 diabetes mellitus.
Study I
In comparison with mitral pulse wave Doppler, Tissue Doppler Imaging
(TDI), a relatively pre-load independent technique, may improve the early
identification of patients with diastolic dysfunction. Fifteen controls
without heart failure, 30 patients with heart failure, were studied, 15
patients with diastolic left ventricular dysfunction and 15 with systolic
left ventricular dysfunction. All the patients with diastolic heart
failure were identified by mitral pulse wave Doppler or TDI, but only 11
were identified by atrio-ventricular plane displacement. The number of
false positive patients were eight, ten and nine, respectively (p<0.01,
p<0.05 and NS) for each of the three methods.
Study II
Eighty-seven patients with type 2 diabetes classified as having no
(n=60), mild (n=13) or moderate (n=14) left ventricular diastolic
dysfunction by Doppler echocardiography and TDI were investigated with
Velocity Vector Imaging (VVI) which evaluates myocardial deformation
(strain). Left atrial volume was larger in patients with moderate
diastolic dysfunction compared with mild or no diastolic dysfunction
(p=0.01). Left atrial roof strain distinguished no diastolic dysfunction
from mild and moderate diastolic dysfunction (p=0.0073). Systolic left
atrial strain correlated to total emptying fraction (r=0.70, p<0.0001)
and inversely to left atrial volume (r=-0.35, p=0.0009).
Studies III-IV
Thirty-nine patients with type 2 diabetes and signs of diastolic
dysfunction but no other cardiovascular disease manifestations were
randomly assigned to glucose normalisation by insulin (I-group; n=21) or
oral glucose-lowering agents (O-group; n=18). Myocardial diastolic
dysfunction and coronary flow reserve were studied with Doppler
echocardiography, including TDI and myocardial contrast-enhanced
echocardiography. Fasting glucose and HbA1c were normalised in both
groups, but this did not significantly influence myocardial diastolic
dysfunction in either group (p=0.65). There was no difference in coronary
flow reserve before and after improved glycaemic control. Twenty-two of
the patients (I-group n=10; O-group n=12) were also investigated in terms
of endothelial function and skin microcirculation by brachial artery
flowmediated dilatation (FMD) and laser Doppler fluxmetry respectively.
Glycaemic normalisation did not improve microcirculation. A reduction in
FMD from 6.0 卤 2.2 to 4.7 卤 3.0% was observed in the I-group (p=0.037),
but there was no change in the O-group (4.3卤2.3 to 4.7卤3.3%; p=0.76). The
between-group difference was not significant (p=0.12).
Conclusions
TDI is useful for diagnosing diastolic myocardial dysfunction, with
accuracy similar to that of conventional echocardiography including
mitral pulse wave Doppler flow. Left atrial deformation, measured as
regional and overall systolic strain, is impaired in patients with type 2
diabetes mellitus and mild to moderate left ventricular diastolic
dysfunction and offers new information on regional LA function and LA
volumes. Further, it may add to traditional Doppler echocardiography
measurements for diagnosis of diastolic dysfunction. The hypothesis that
improved glycaemic control would reverse early signs of myocardial
diastolic and endothelial dysfunction in patients with type 2 diabetes
was not proven. Whether it is possible to influence more pronounced
dysfunction, particularly in patients with less well-controlled and
long-standing diabetes, remains to be further explored in controlled
clinical trials
A Survey of Empirical Results on Program Slicing
International audienceBACKGROUND:Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.METHODS:This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0路90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2路5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.FINDINGS:Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0路72, 95% CI 0路57-0路90, p=0路0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0路54 95% CI 0路35-0路82, p=0路0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0路86, 95% CI 0路69-1路08, p=0路19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0路67, 95% CI 0路45-1路00, p=0路05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1路61, 95% CI 1路12-2路31, p=0路0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1路68, 95% CI 1路17-2路40; p=0路0043).INTERPRETATION:Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding